Foghorn Therapeutics Announces Change to Board of Directors
Retrieved on:
Wednesday, August 31, 2022
Howard Hughes Medical Institute, Security (finance), Matej Cigale, Research, Disease, Board, LinkedIn, Forward-looking statement, Gene expression, HHMI, U.S. Securities and Exchange Commission, GLOBE, Leadership, Biology, Nasdaq, Company, Twitter, Chromatin, Pharmaceutical industry, Management, Foghorn
In accordance with HHMIs rules, she has resigned from Foghorns Board of Directors, effective August 31, 2022.
Key Points:
- In accordance with HHMIs rules, she has resigned from Foghorns Board of Directors, effective August 31, 2022.
- Dr. Kadoch has become Scientific Advisor to the Board and will continue to participate on Foghorns Scientific Advisory Board.
- I am excited to continue working with the Board and Company as Scientific Advisor to the Board, said Dr. Kadoch.
- Douglas Cole, M.D., Flagship Pioneering Managing Partner, Foghorn Co-Founder and Chairman of the Board, continued, I want to thank Cigall for her significant contributions to Foghorn as a co-founder and founding Board member.